Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: lymphoid neoplasms. Leukemia 2022;36:1720–1748.

• PubMed
Alaggio R, Amador C, Anagnostopoulos I, The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: lymphoid neoplasms. Leukemia 2022;36:1720–1748.)| false
• Search Google Scholar
• Export Citation

Campo E, Jaffe ES, Cook JR, et al. The international consensus classification of mature lymphoid neoplasms: a report from the Clinical Advisory Committee. Blood 2022;140:1229–1253.

• PubMed
Campo E, Jaffe ES, Cook JR, The international consensus classification of mature lymphoid neoplasms: a report from the Clinical Advisory Committee. Blood 2022;140:1229–1253.)| false
• Search Google Scholar
• Export Citation

Navarro A, Clot G, Royo C, et al. Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features. Cancer Res 2012;72:5307–5316.

• PubMed
Navarro A, Clot G, Royo C, Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features. Cancer Res 2012;72:5307–5316.)| false
• Search Google Scholar
• Export Citation

Dreyling M, Klapper W, Rule S. Blastoid and pleomorphic mantle cell lymphoma: still a diagnostic and therapeutic challenge! Blood 2018;132:2722–2729.

• PubMed
Dreyling M, Klapper W, Rule S. Blastoid and pleomorphic mantle cell lymphoma: still a diagnostic and therapeutic challenge! Blood 2018;132:2722–2729.)| false
• Search Google Scholar
• Export Citation

Fernàndez V, Salamero O, Espinet B, et al. Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. Cancer Res 2010;70:1408–1418.

• PubMed
Fernàndez V, Salamero O, Espinet B, Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. Cancer Res 2010;70:1408–1418.)| false
• Search Google Scholar
• Export Citation

Ondrejka SL, Lai R, Smith SD, et al. Indolent mantle cell leukemia: a clinicopathological variant characterized by isolated lymphocytosis, interstitial bone marrow involvement, kappa light chain restriction, and good prognosis. Haematologica 2011;96:1121–1127.

• PubMed
Ondrejka SL, Lai R, Smith SD, Indolent mantle cell leukemia: a clinicopathological variant characterized by isolated lymphocytosis, interstitial bone marrow involvement, kappa light chain restriction, and good prognosis. Haematologica 2011;96:1121–1127.)| false
• Search Google Scholar
• Export Citation

Eskelund CW, Dahl C, Hansen JW, et al. TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy. Blood 2017;130:1903–1910.

• PubMed
Eskelund CW, Dahl C, Hansen JW, TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy. Blood 2017;130:1903–1910.)| false
• Search Google Scholar
• Export Citation

Obr A, Klener P, Furst T, et al. A high TP53 mutation burden is a strong predictor of primary refractory mantle cell lymphoma. Br J Haematol 2020;191:e103–106.

• PubMed
Obr A, Klener P, Furst T, A high TP53 mutation burden is a strong predictor of primary refractory mantle cell lymphoma. Br J Haematol 2020;191:e103–106.)| false
• Search Google Scholar
• Export Citation

Ferrero S, Rossi D, Rinaldi A, et al. KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study. Haematologica 2020;105:1604–1612.

• PubMed
Ferrero S, Rossi D, Rinaldi A, KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study. Haematologica 2020;105:1604–1612.)| false
• Search Google Scholar
• Export Citation

Tam CS, Gregory GP, Ku M, et al. Recommendation for TP53 mutation testing in newly diagnosed mantle cell lymphoma: a statement from working groups sponsored by the Victorian Comprehensive Cancer Centre. Intern Med J 2022;52:1286–1287.

• PubMed
Tam CS, Gregory GP, Ku M, Recommendation for TP53 mutation testing in newly diagnosed mantle cell lymphoma: a statement from working groups sponsored by the Victorian Comprehensive Cancer Centre. Intern Med J 2022;52:1286–1287.)| false
• Search Google Scholar
• Export Citation

Graf SA, Stevenson PA, Holmberg LA, et al. Maintenance rituximab after autologous stem cell transplantation in patients with mantle cell lymphoma. Ann Oncol 2015;26:2323–2328.

• PubMed
Graf SA, Stevenson PA, Holmberg LA, Maintenance rituximab after autologous stem cell transplantation in patients with mantle cell lymphoma. Ann Oncol 2015;26:2323–2328.)| false
• Search Google Scholar
• Export Citation

Le Gouill S, Thieblemont C, Oberic L, et al. Rituximab after autologous stem cell transplantation in mantle cell lymphoma. N Engl J Med 2017;377:1250–1260.

• PubMed
Le Gouill S, Thieblemont C, Oberic L, Rituximab after autologous stem cell transplantation in mantle cell lymphoma. N Engl J Med 2017;377:1250–1260.)| false
• Search Google Scholar
• Export Citation

Klener P, Salek D, Pytlik R, et al. Rituximab maintenance significantly prolongs progression-free survival of patients with newly diagnosed mantle cell lymphoma treated with the Nordic MCL2 protocol and autologous stem cell transplantation. Am J Hematol 2019;94:E50–53.

• PubMed
Klener P, Salek D, Pytlik R, Rituximab maintenance significantly prolongs progression-free survival of patients with newly diagnosed mantle cell lymphoma treated with the Nordic MCL2 protocol and autologous stem cell transplantation. Am J Hematol 2019;94:E50–53.)| false
• Search Google Scholar
• Export Citation

Kluin-Nelemans HC, Hoster E, Hermine O, et al. Treatment of older patients with mantle cell lymphoma (MCL): long-term follow-up of the randomized European MCL Elderly Trial. J Clin Oncol 2020;38:248–256.

• PubMed
Kluin-Nelemans HC, Hoster E, Hermine O, Treatment of older patients with mantle cell lymphoma (MCL): long-term follow-up of the randomized European MCL Elderly Trial. J Clin Oncol 2020;38:248–256.)| false
• Search Google Scholar
• Export Citation

Hermine O, Jiang L, Walewski J, et al. High-dose cytarabine and autologous stem-cell transplantation in mantle cell lymphoma: long-term follow-up of the randomized mantle cell lymphoma younger trial of the European Mantle Cell Lymphoma Network. J Clin Oncol 2023;41:479–484.

• PubMed
Hermine O, Jiang L, Walewski J, High-dose cytarabine and autologous stem-cell transplantation in mantle cell lymphoma: long-term follow-up of the randomized mantle cell lymphoma younger trial of the European Mantle Cell Lymphoma Network. J Clin Oncol 2023;41:479–484.)| false
• Search Google Scholar
• Export Citation

Dreyling M, Doorduijn JK, Gine E, et al. Efficacy and safety of ibrutinib combined with standard first-line treatment or as substitute for autologous stem cell transplantation in younger patients with mantle cell lymphoma: results from the randomized Triangle Trial by the European MCL Network. Blood 2022;140(Suppl 1):1–3.

• PubMed
Dreyling M, Doorduijn JK, Gine E, Efficacy and safety of ibrutinib combined with standard first-line treatment or as substitute for autologous stem cell transplantation in younger patients with mantle cell lymphoma: results from the randomized Triangle Trial by the European MCL Network. Blood 2022;140(Suppl 1):1–3.)| false
• Search Google Scholar
• Export Citation

Byrd JC, Hillmen P, Ghia P, et al. Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial. J Clin Oncol 2021;39:3441–3452.

• PubMed
Byrd JC, Hillmen P, Ghia P, Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial. J Clin Oncol 2021;39:3441–3452.)| false
• Search Google Scholar
• Export Citation

Brown JR, Eichhorst B, Hillmen P, et al. Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med 2023;388:319–332.

• PubMed
Brown JR, Eichhorst B, Hillmen P, Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med 2023;388:319–332.)| false
• Search Google Scholar
• Export Citation

Wang ML, Jurczak W, Jerkeman M, et al. Ibrutinib plus bendamustine and rituximab in untreated mantle-cell lymphoma. N Engl J Med 2022;386:2482–2494.

• PubMed
Wang ML, Jurczak W, Jerkeman M, Ibrutinib plus bendamustine and rituximab in untreated mantle-cell lymphoma. N Engl J Med 2022;386:2482–2494.)| false
• Search Google Scholar
• Export Citation

Khouri IF, Saliba RM, Okoroji GJ, et al. Long-term follow-up of autologous stem cell transplantation in patients with diffuse mantle cell lymphoma in first disease remission: the prognostic value of beta2-microglobulin and the tumor score. Cancer 2003;98:2630–2635.

• PubMed
Khouri IF, Saliba RM, Okoroji GJ, Long-term follow-up of autologous stem cell transplantation in patients with diffuse mantle cell lymphoma in first disease remission: the prognostic value of beta2-microglobulin and the tumor score. Cancer 2003;98:2630–2635.)| false
• Search Google Scholar
• Export Citation

Dreyling M, Lenz G, Hoster E, et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood 2005;105:2677–2684.

• PubMed
Dreyling M, Lenz G, Hoster E, Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood 2005;105:2677–2684.)| false
• Search Google Scholar
• Export Citation

Zoellner AK, Unterhalt M, Stilgenbauer S, et al. Long-term survival of patients with mantle cell lymphoma after autologous haematopoietic stem-cell transplantation in first remission: a post-hoc analysis of an open-label, multicentre, randomised, phase 3 trial. Lancet Haematol 2021;8:e648–657.

• PubMed
Zoellner AK, Unterhalt M, Stilgenbauer S, Long-term survival of patients with mantle cell lymphoma after autologous haematopoietic stem-cell transplantation in first remission: a post-hoc analysis of an open-label, multicentre, randomised, phase 3 trial. Lancet Haematol 2021;8:e648–657.)| false
• Search Google Scholar
• Export Citation

Thieblemont C, Antal D, Lacotte-Thierry L, et al. Chemotherapy with rituximab followed by high-dose therapy and autologous stem cell transplantation in patients with mantle cell lymphoma. Cancer 2005;104:1434–1441.

• PubMed
Thieblemont C, Antal D, Lacotte-Thierry L, Chemotherapy with rituximab followed by high-dose therapy and autologous stem cell transplantation in patients with mantle cell lymphoma. Cancer 2005;104:1434–1441.)| false
• Search Google Scholar
• Export Citation

Till BG, Gooley TA, Crawford N, et al. Effect of remission status and induction chemotherapy regimen on outcome of autologous stem cell transplantation for mantle cell lymphoma. Leuk Lymphoma 2008;49:1062–1073.

• PubMed
Till BG, Gooley TA, Crawford N, Effect of remission status and induction chemotherapy regimen on outcome of autologous stem cell transplantation for mantle cell lymphoma. Leuk Lymphoma 2008;49:1062–1073.)| false
• Search Google Scholar
• Export Citation

van’t Veer MB, de Jong D, MacKenzie M, et al. High-dose Ara-C and beam with autograft rescue in R-CHOP responsive mantle cell lymphoma patients. Br J Haematol 2009;144:524–530.

• PubMed
van’t Veer MB, de Jong D, MacKenzie M, High-dose Ara-C and beam with autograft rescue in R-CHOP responsive mantle cell lymphoma patients. Br J Haematol 2009;144:524–530.)| false
• Search Google Scholar
• Export Citation

Metzner B, Müller TH, Casper J, et al. Long-term outcome in patients with mantle cell lymphoma following high-dose therapy and autologous stem cell transplantation. Eur J Haematol 2023;111:220–228.

• PubMed
Metzner B, Müller TH, Casper J, Long-term outcome in patients with mantle cell lymphoma following high-dose therapy and autologous stem cell transplantation. Eur J Haematol 2023;111:220–228.)| false
• Search Google Scholar
• Export Citation

Wang M, Rule S, Zinzani PL, et al. Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma. Leukemia 2019;33:2762–2766.

• PubMed
Wang M, Rule S, Zinzani PL, Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma. Leukemia 2019;33:2762–2766.)| false
• Search Google Scholar
• Export Citation

Tam CS, Opat S, Simpson D, et al. Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma. Blood Adv 2021;5:2577–2585.

• PubMed
Tam CS, Opat S, Simpson D, Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma. Blood Adv 2021;5:2577–2585.)| false
• Search Google Scholar
• Export Citation

Wang M, Fayad L, Wagner-Bartak N, et al. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. Lancet Oncol 2012;13:716–723.

• PubMed
Wang M, Fayad L, Wagner-Bartak N, Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. Lancet Oncol 2012;13:716–723.)| false
• Search Google Scholar
• Export Citation

Wang M, Schuster SJ, Phillips T, et al. Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004). J Hematol Oncol 2017;10:171.

• PubMed
Wang M, Schuster SJ, Phillips T, Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004). J Hematol Oncol 2017;10:171.)| false
• Search Google Scholar
• Export Citation

Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 2013;369:507–516.

• PubMed
Wang ML, Rule S, Martin P, Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 2013;369:507–516.)| false
• Search Google Scholar
• Export Citation

Wang ML, Blum KA, Martin P, et al. Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. Blood 2015;126:739–745.

• PubMed
Wang ML, Blum KA, Martin P, Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. Blood 2015;126:739–745.)| false
• Search Google Scholar
• Export Citation

Jain P, Romaguera J, Srour SA, et al. Four-year follow-up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed/refractory mantle cell lymphoma (MCL). Br J Haematol 2018;182:404–411.

• PubMed
Jain P, Romaguera J, Srour SA, Four-year follow-up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed/refractory mantle cell lymphoma (MCL). Br J Haematol 2018;182:404–411.)| false
• Search Google Scholar
• Export Citation

Rule S, Jurczak W, Jerkeman M, et al. Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study. Leukemia 2018;32:1799–1803.

• PubMed
Rule S, Jurczak W, Jerkeman M, Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study. Leukemia 2018;32:1799–1803.)| false
• Search Google Scholar
• Export Citation

McCulloch R, Lewis D, Crosbie N, et al. Ibrutinib for mantle cell lymphoma at first relapse: a United Kingdom real-world analysis of outcomes in 211 patients. Br J Haematol 2021;193:290–298.

• PubMed
McCulloch R, Lewis D, Crosbie N, Ibrutinib for mantle cell lymphoma at first relapse: a United Kingdom real-world analysis of outcomes in 211 patients. Br J Haematol 2021;193:290–298.)| false
• Search Google Scholar
• Export Citation

Eyre TA, Walter HS, Iyengar S, et al. Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy. Haematologica 2019;104:e68–71.

• PubMed
Eyre TA, Walter HS, Iyengar S, Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy. Haematologica 2019;104:e68–71.)| false
• Search Google Scholar
• Export Citation

Zhao S, Kanagal-Shamanna R, Navsaria L, et al. Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) — outcomes and mutation profile from venetoclax resistant MCL patients. Am J Hematol 2020;95:623–629.

• PubMed
Zhao S, Kanagal-Shamanna R, Navsaria L, Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) — outcomes and mutation profile from venetoclax resistant MCL patients. Am J Hematol 2020;95:623–629.)| false
• Search Google Scholar
• Export Citation

Awan FT, Schuh A, Brown JR, et al. Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib. Blood Adv 2019;3:1553–1562.

• PubMed
Awan FT, Schuh A, Brown JR, Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib. Blood Adv 2019;3:1553–1562.)| false
• Search Google Scholar
• Export Citation

Rogers KA, Thompson PA, Allan JN, et al. Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia. Haematologica 2021;106:2364–2373.

• PubMed
Rogers KA, Thompson PA, Allan JN, Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia. Haematologica 2021;106:2364–2373.)| false
• Search Google Scholar
• Export Citation

Shadman M, Flinn IW, Levy MY, et al. Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study. Lancet Haematol 2023;10:e35–45.

• PubMed
Shadman M, Flinn IW, Levy MY, Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study. Lancet Haematol 2023;10:e35–45.)| false
• Search Google Scholar
• Export Citation

Wang M, Munoz J, Goy A, et al. Three-year follow-up of KTE-X19 in patients with relapsed/refractory mantle cell lymphoma, including high-risk subgroups, in the ZUMA-2 study. J Clin Oncol 2023;41:555–567.

• PubMed
Wang M, Munoz J, Goy A, Three-year follow-up of KTE-X19 in patients with relapsed/refractory mantle cell lymphoma, including high-risk subgroups, in the ZUMA-2 study. J Clin Oncol 2023;41:555–567.)| false
• Search Google Scholar
• Export Citation

Martin P, Maddocks K, Leonard JP, et al. Postibrutinib outcomes in patients with mantle cell lymphoma. Blood 2016;127:1559–1563.

• PubMed
Martin P, Maddocks K, Leonard JP, Postibrutinib outcomes in patients with mantle cell lymphoma. Blood 2016;127:1559–1563.)| false
• Search Google Scholar
• Export Citation

Jain P, Kanagal-Shamanna R, Zhang S, et al. Outcomes of relapsed mantle cell lymphoma patients after discontinuing acalabrutinib. Am J Hematol 2021;96:E137–140.

• PubMed
Jain P, Kanagal-Shamanna R, Zhang S, Outcomes of relapsed mantle cell lymphoma patients after discontinuing acalabrutinib. Am J Hematol 2021;96:E137–140.)| false
• Search Google Scholar
• Export Citation

Hess G, Dreyling M, Oberic L, et al. Real-world experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: the SCHOLAR-2 retrospective chart review study. Br J Haematol 2022;202:749–759.

• PubMed
Hess G, Dreyling M, Oberic L, Real-world experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: the SCHOLAR-2 retrospective chart review study. Br J Haematol 2022;202:749–759.)| false
• Search Google Scholar
• Export Citation

Cohen JB, Shah NN, Alencar AJ, et al. MCL-133 pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in previously treated mantle cell lymphoma: updated results from the phase 1/2 BRUIN study. Clin Lymphoma Myeloma Leuk 2022;22(Suppl 2):S394–395.

• PubMed
Cohen JB, Shah NN, Alencar AJ, MCL-133 pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in previously treated mantle cell lymphoma: updated results from the phase 1/2 BRUIN study. Clin Lymphoma Myeloma Leuk 2022;22(Suppl 2):S394–395.)| false
• Search Google Scholar
• Export Citation

Wang ML, Shah NN, Jurczak W, et al. Efficacy of pirtobrutinib in covalent BTK-inhibitor pre-treated relapsed/refractory mantle cell lymphoma: additional patients and extended follow-up from the phase 1/2 BRUIN study. Blood 2022;140(Suppl 1):Abstract 623.

• PubMed
Wang ML, Shah NN, Jurczak W, Efficacy of pirtobrutinib in covalent BTK-inhibitor pre-treated relapsed/refractory mantle cell lymphoma: additional patients and extended follow-up from the phase 1/2 BRUIN study. Blood 2022;140(Suppl 1):Abstract 623.)| false
• Search Google Scholar
• Export Citation

Munshi PN, Hamadani M, Kumar A, et al. American Society of Transplantation and Cellular Therapy, Center of International Blood and Marrow Transplant Research, and European Society for Blood and Marrow Transplantation clinical practice recommendations for transplantation and cellular therapies in mantle cell lymphoma. Transplant Cell Ther 2021;27:720–728.

• PubMed
Munshi PN, Hamadani M, Kumar A, American Society of Transplantation and Cellular Therapy, Center of International Blood and Marrow Transplant Research, and European Society for Blood and Marrow Transplantation clinical practice recommendations for transplantation and cellular therapies in mantle cell lymphoma. Transplant Cell Ther 2021;27:720–728.)| false
• Search Google Scholar
• Export Citation

Neelapu SS, Chavez J, Sehgal AR, et al. 3-year follow-up analysis of ZUMA-5: a phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL). Blood 2022;140(Suppl 1):Abstract 705.

• PubMed
Neelapu SS, Chavez J, Sehgal AR, 3-year follow-up analysis of ZUMA-5: a phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL). Blood 2022;140(Suppl 1):Abstract 705.)| false
• Search Google Scholar
• Export Citation

Fowler NH, Dickinson M, Dreyling M, et al. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. Nat Med 2022;28:325–332.

• PubMed
Fowler NH, Dickinson M, Dreyling M, Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. Nat Med 2022;28:325–332.)| false
• Search Google Scholar
• Export Citation

Morschhauser F, Tilly H, Chaidos A, et al. Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial. Lancet Oncol 2020;21:1433–1442.

• PubMed
Morschhauser F, Tilly H, Chaidos A, Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial. Lancet Oncol 2020;21:1433–1442.)| false
• Search Google Scholar
• Export Citation

Dreyling M, Santoro A, Mollica L, et al. Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study. Am J Hematol 2020;95:362–371.

• PubMed
Dreyling M, Santoro A, Mollica L, Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study. Am J Hematol 2020;95:362–371.)| false
• Search Google Scholar
• Export Citation

Flinn IW, Miller CB, Ardeshna KM, et al. DYNAMO: a phase II study of duvelisib (IPI-145) in patients with refractory indolent non-Hodgkin lymphoma. J Clin Oncol 2019;37:912–922.

• PubMed
Flinn IW, Miller CB, Ardeshna KM, DYNAMO: a phase II study of duvelisib (IPI-145) in patients with refractory indolent non-Hodgkin lymphoma. J Clin Oncol 2019;37:912–922.)| false
• Search Google Scholar
• Export Citation

Gopal AK, Kahl BS, de Vos S, et al. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med 2014;370:1008–1018.

• PubMed
Gopal AK, Kahl BS, de Vos S, PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med 2014;370:1008–1018.)| false
• Search Google Scholar
• Export Citation

Gopal AK, Kahl BS, Flowers CR, et al. Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy. Blood 2017;129:3037–3039.

• PubMed
Gopal AK, Kahl BS, Flowers CR, Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy. Blood 2017;129:3037–3039.)| false
• Search Google Scholar
• Export Citation

Fowler NH, Samaniego F, Jurczak W, et al. Umbralisib, a dual PI3Kδ/CK1ε inhibitor in patients with relapsed or refractory indolent lymphoma. J Clin Oncol 2021;39:1609–1618.

• PubMed
Fowler NH, Samaniego F, Jurczak W, Umbralisib, a dual PI3Kδ/CK1ε inhibitor in patients with relapsed or refractory indolent lymphoma. J Clin Oncol 2021;39:1609–1618.)| false
• Search Google Scholar
• Export Citation

Richardson NC, Kasamon Y, Pazdur R, et al. The saga of PI3K inhibitors in haematological malignancies: survival is the ultimate safety endpoint. Lancet Oncol 2022;23:563–566.

• PubMed
Richardson NC, Kasamon Y, Pazdur R, The saga of PI3K inhibitors in haematological malignancies: survival is the ultimate safety endpoint. Lancet Oncol 2022;23:563–566.)| false
• Search Google Scholar
• Export Citation

Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med 1995;333:1540–1545.

• PubMed
Philip T, Guglielmi C, Hagenbeek A, Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med 1995;333:1540–1545.)| false
• Search Google Scholar
• Export Citation

Vose JM, Zhang MJ, Rowlings PA, et al. Autologous transplantation for diffuse aggressive non-Hodgkin’s lymphoma in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol 2001;19:406–413.

• PubMed
Vose JM, Zhang MJ, Rowlings PA, Autologous transplantation for diffuse aggressive non-Hodgkin’s lymphoma in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol 2001;19:406–413.)| false
• Search Google Scholar
• Export Citation

Caballero MD, Pérez-Simón JA, Iriondo A, et al. High-dose therapy in diffuse large cell lymphoma: results and prognostic factors in 452 patients from the GEL-TAMO Spanish Cooperative Group. Ann Oncol 2003;14:140–151.

• PubMed
Caballero MD, Pérez-Simón JA, Iriondo A, High-dose therapy in diffuse large cell lymphoma: results and prognostic factors in 452 patients from the GEL-TAMO Spanish Cooperative Group. Ann Oncol 2003;14:140–151.)| false
• Search Google Scholar
• Export Citation

Rodriguez J, Caballero MD, Gutierrez A, et al. Autologous stem-cell transplantation in diffuse large B-cell non-Hodgkin’s lymphoma not achieving complete response after induction chemotherapy: the GEL/TAMO experience. Ann Oncol 2004;15:1504–1509.

• PubMed
Rodriguez J, Caballero MD, Gutierrez A, Autologous stem-cell transplantation in diffuse large B-cell non-Hodgkin’s lymphoma not achieving complete response after induction chemotherapy: the GEL/TAMO experience. Ann Oncol 2004;15:1504–1509.)| false
• Search Google Scholar
• Export Citation

Shah NN, Ahn KW, Litovich C, et al. Is autologous transplant in relapsed DLBCL patients achieving only a PET+ PR appropriate in the CAR T-cell era? Blood 2021;137:1416–1423.

• PubMed
Shah NN, Ahn KW, Litovich C, Is autologous transplant in relapsed DLBCL patients achieving only a PET+ PR appropriate in the CAR T-cell era? Blood 2021;137:1416–1423.)| false
• Search Google Scholar
• Export Citation

Mounier N, Canals C, Gisselbrecht C, et al. High-dose therapy and autologous stem cell transplantation in first relapse for diffuse large B cell lymphoma in the rituximab era: an analysis based on data from the European Blood and Marrow Transplantation Registry. Biol Blood Marrow Transplant 2012;18:788–793.

• PubMed
Mounier N, Canals C, Gisselbrecht C, High-dose therapy and autologous stem cell transplantation in first relapse for diffuse large B cell lymphoma in the rituximab era: an analysis based on data from the European Blood and Marrow Transplantation Registry. Biol Blood Marrow Transplant 2012;18:788–793.)| false
• Search Google Scholar
• Export Citation

Shadman M, Pasquini M, Ahn KW, et al. Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission. Blood 2022;139:1330–1339.

• PubMed
Shadman M, Pasquini M, Ahn KW, Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission. Blood 2022;139:1330–1339.)| false
• Search Google Scholar
• Export Citation

Sehn LH, Herrera AF, Flowers CR, et al. Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 2020;38:155–165.

• PubMed
Sehn LH, Herrera AF, Flowers CR, Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 2020;38:155–165.)| false
• Search Google Scholar
• Export Citation

Salles G, Duell J, González-Barca E, et al. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. Lancet Oncol 2020;21:978–988.

• PubMed
Salles G, Duell J, González-Barca E, Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. Lancet Oncol 2020;21:978–988.)| false
• Search Google Scholar
• Export Citation

Caimi PF, Ai W, Alderuccio JP, et al. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol 2021;22:790–800.

• PubMed
Caimi PF, Ai W, Alderuccio JP, Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol 2021;22:790–800.)| false
• Search Google Scholar
• Export Citation

Kalakonda N, Maerevoet M, Cavallo F, et al. Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial. Lancet Haematol 2020;7:e511–522.

• PubMed
Kalakonda N, Maerevoet M, Cavallo F, Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial. Lancet Haematol 2020;7:e511–522.)| false
• Search Google Scholar
• Export Citation

Van Den Neste E, Schmitz N, Mounier N, et al. Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the international CORAL study. Bone Marrow Transplant 2016;51:51–57.

• PubMed
Van Den Neste E, Schmitz N, Mounier N, Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the international CORAL study. Bone Marrow Transplant 2016;51:51–57.)| false
• Search Google Scholar
• Export Citation

Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood 2017;130:1800–1808.

• PubMed
Crump M, Neelapu SS, Farooq U, Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood 2017;130:1800–1808.)| false
• Search Google Scholar
• Export Citation

Ayers EC, Li S, Medeiros LJ, et al. Outcomes in patients with aggressive B-cell non-Hodgkin lymphoma after intensive frontline treatment failure. Cancer 2020;126:293–303.

• PubMed
Ayers EC, Li S, Medeiros LJ, Outcomes in patients with aggressive B-cell non-Hodgkin lymphoma after intensive frontline treatment failure. Cancer 2020;126:293–303.)| false
• Search Google Scholar
• Export Citation

Neelapu SS, Jacobson CA, Ghobadi A, et al. Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma. Blood 2023;141:2307–2315.

• PubMed
Neelapu SS, Jacobson CA, Ghobadi A, Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma. Blood 2023;141:2307–2315.)| false
• Search Google Scholar
• Export Citation

Schuster SJ, Tam CS, Borchmann P, et al. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol 2021;22:1403–1415.

• PubMed
Schuster SJ, Tam CS, Borchmann P, Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol 2021;22:1403–1415.)| false
• Search Google Scholar
• Export Citation

Abramson JS, Palomba ML, Gordon LI, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet 2020;396:839–852.

• PubMed
Abramson JS, Palomba ML, Gordon LI, Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet 2020;396:839–852.)| false
• Search Google Scholar
• Export Citation

Sehgal A, Hoda D, Riedell PA, et al. Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study. Lancet Oncol 2022;23:1066–1077.

• PubMed
Sehgal A, Hoda D, Riedell PA, Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study. Lancet Oncol 2022;23:1066–1077.)| false
• Search Google Scholar
• Export Citation

Locke FL, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N Engl J Med 2022;386:640–654.

• PubMed
Locke FL, Miklos DB, Jacobson CA, Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N Engl J Med 2022;386:640–654.)| false
• Search Google Scholar
• Export Citation

Abramson JS, Solomon SR, Arnason J, et al. Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study. Blood 2023;141:1675–1684.

• PubMed
Abramson JS, Solomon SR, Arnason J, Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study. Blood 2023;141:1675–1684.)| false
• Search Google Scholar
• Export Citation

Byrne M, Oluwole OO, Savani B, et al. Understanding and managing large B cell lymphoma relapses after chimeric antigen receptor T cell therapy. Biol Blood Marrow Transplant 2019;25:e344–351.

• PubMed
Byrne M, Oluwole OO, Savani B, Understanding and managing large B cell lymphoma relapses after chimeric antigen receptor T cell therapy. Biol Blood Marrow Transplant 2019;25:e344–351.)| false
• Search Google Scholar
• Export Citation

Chow VA, Gopal AK, Maloney DG, et al. Outcomes of patients with large B-cell lymphomas and progressive disease following CD19-specific CAR T-cell therapy. Am J Hematol 2019;94:E209–213.

• PubMed
Chow VA, Gopal AK, Maloney DG, Outcomes of patients with large B-cell lymphomas and progressive disease following CD19-specific CAR T-cell therapy. Am J Hematol 2019;94:E209–213.)| false
• Search Google Scholar
• Export Citation

Budde LE, Sehn LH, Matasar M, et al. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. Lancet Oncol 2022;23:1055–1065.

• PubMed
Budde LE, Sehn LH, Matasar M, Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. Lancet Oncol 2022;23:1055–1065.)| false
• Search Google Scholar
• Export Citation

Bartlett NL, Sehn LH, Matasar MJ, et al. Mosunetuzumab monotherapy demonstrates durable efficacy with a manageable safety profile in patients with relapsed/refractory follicular lymphoma who received ≥2 prior therapies: updated results from a pivotal phase II study. Blood 2022;140(Suppl 1):Abstract 623.

• PubMed
Bartlett NL, Sehn LH, Matasar MJ, Mosunetuzumab monotherapy demonstrates durable efficacy with a manageable safety profile in patients with relapsed/refractory follicular lymphoma who received ≥2 prior therapies: updated results from a pivotal phase II study. Blood 2022;140(Suppl 1):Abstract 623.)| false
• Search Google Scholar
• Export Citation

Thieblemont C, Phillips T, Ghesquieres H, et al. Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I/II trial. J Clin Oncol 2023;41:2238–2247.

• PubMed
Thieblemont C, Phillips T, Ghesquieres H, Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I/II trial. J Clin Oncol 2023;41:2238–2247.)| false
• Search Google Scholar
• Export Citation

Dickinson MJ, Carlo-Stella C, Morschhauser F, et al. Glofitamab for relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med 2022;387:2220–2231.

• PubMed
Dickinson MJ, Carlo-Stella C, Morschhauser F, Glofitamab for relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med 2022;387:2220–2231.)| false
• Search Google Scholar
• Export Citation

Falchi L, Carlo-Stella C, Morschhauser F, et al. Glofitamab monotherapy in pts with relapsed/refractory (R/R) large B-cell lymphoma (LBCL): extended follow-up and landmark analyses from a pivotal phase II study. J Clin Oncol 2023;41(Suppl):Abstract 7550.

• PubMed
Falchi L, Carlo-Stella C, Morschhauser F, Glofitamab monotherapy in pts with relapsed/refractory (R/R) large B-cell lymphoma (LBCL): extended follow-up and landmark analyses from a pivotal phase II study. J Clin Oncol 2023;41(Suppl):Abstract 7550.)| false
• Search Google Scholar
• Export Citation

Lee DW, Santomasso BD, Locke FL, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant 2019;25:625–638.

• PubMed
Lee DW, Santomasso BD, Locke FL, ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant 2019;25:625–638.)| false
• Search Google Scholar
• Export Citation

Neelapu SS, Tummala S, Kebriaei P, et al. Chimeric antigen receptor T-cell therapy —assessment and management of toxicities. Nat Rev Clin Oncol 2018;15:47–62.

• PubMed
Neelapu SS, Tummala S, Kebriaei P, Chimeric antigen receptor T-cell therapy —assessment and management of toxicities. Nat Rev Clin Oncol 2018;15:47–62.)| false
• Search Google Scholar
• Export Citation

Jain T, Olson TS, Locke FL. How I treat cytopenias after CAR T-cell therapy. Blood 2023;141:2460–2469.

• PubMed
Jain T, Olson TS, Locke FL. How I treat cytopenias after CAR T-cell therapy. Blood 2023;141:2460–2469.)| false
• Search Google Scholar
• Export Citation